 |
|
|
| |
Validation of a Modified Pediatric Formulation of Sofosbuvir and Daclatasvir in Genotype-4 HCV-infected Children Weighing 17-35 Kg
|
| |
| |
EASL 2024 June 5-8
Ahmed Farrag 1, Maggie Abbassi 1, Fatma Ebeid 2, Tim Cressey 3, Philippa Easterbrook 4, Nirmeen Sabry 5, Manal El-Sayed 6
|
| |
|
|
|
|
|
